在英国社区用于紧急管理的药物:临床实践研究数据链接回顾数据库研究研究
Yuanjun Ma1, Chao Lu2, Peggy Hastie2
1UCB, Slough, UK.
Epilepsia open
|May 14, 2025
概括
2019年,6.7%的患者获得了抗发作紧急药物处方. 医疗保健资源的高利用率表明,在管理发作紧急情况方面存在挑战,这表明需要新的治疗模式.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 影响全球数百万人,其中一些人经历了长时间的发作或发作集群,需要紧急干预.
- 抗发作紧急药物,主要是二类药物,对于立即管理至关重要.
- 了解这些药物的处方模式和医疗保健利用对于优化患者护理至关重要.
研究的目的:
- 确定英国患者中发作紧急药物处方的流行率.
- 描述接受这些药物的患者,并分析他们的医疗保健资源利用率 (HCRU).
- 识别当前发作和紧急情况管理策略中的潜在缺口.
主要方法:
- 使用临床实践研究数据链 (CPRD-Aurum) 和医院情节统计 (HES) 数据 (2016-2020) 的回顾性队列研究.
- 纳入标准:至少有一次注册的抗发作紧急药物处方的患者.
- 分析包括2019年的患者人口统计,药物类型和HCRU (住院,门诊,急救访问).
主要成果:
- 2019年,在CPRD-Aurum的患者中,6.7%的患者有发作紧急药物处方.
- 口腔米达佐拉姆是最常被处方的药物 (60.6%),其次是直肠迪亚泽帕姆 (19.0%) 和口服二类药物 (20.3%).
- 患有HES链接的患者显示出显著的HCRU:25.1%的住院住院,35.7%的门诊,8.7%的急诊因相关问题.
结论:
- 很大一部分患者需要抗发作紧急药物,口服米达佐拉姆是最常见的.
- 这些患者的高医疗资源利用率突显了发作紧急管理的持续挑战.
- 这些发现表明需要新的治疗模式,例如快速和早期断终止 (REST) 概念,以改善结果.
相关概念视频
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...